Hangzhou Tigermed Consulting Co., Ltd (SHE: 300347)

Market Cap	39.38B
Revenue (ttm)	7.03B
Net Income (ttm)	1.13B
Shares Out	861.29M
EPS (ttm)	1.30
PE Ratio	37.76
Forward PE	22.52
Dividend	0.57 (1.17%)
Ex-Dividend Date	Jul 12, 2024

Volume	4,207,300
Open	50.46
Previous Close	48.73
Day's Range	48.00 - 50.61
52-Week Range	36.12 - 73.19
Beta	0.74
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 24, 2024

About Hangzhou Tigermed Consulting

Hangzhou Tigermed Consulting Co., Ltd provides contract research organization services in the People’s Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data managem...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 9,701
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300347

Financial Performance

In 2023, Hangzhou Tigermed Consulting's revenue was 7.38 billion, an increase of 4.21% compared to the previous year's 7.09 billion. Earnings were 2.02 billion, an increase of 0.91%.